Un update was provided by bioshares on ACL. It contained a...

Un update was provided by bioshares on ACL. It contained a number of interesting comments and conclusions:
Including citing the key reason for the failed ipo being the structure and the immediate windfall for Australian investors,which some US investors found unpalatable.

On Pete Smith's resignation. One of the points of disagreement going forward was how to proceed with the demerger. At this stage, it appears more likely that a demerger will be considered in early 2014, once the Phase III results have been released. This is a more appropriate path, where if the trial is successful, then a substantially higher technology value can be attributed to the spin out.


On GSK's recent quarterly report which saw sales of Arixtra in the US increase to US$31 million in the December quarter, up from the low of US$25 million in the March quarter of that year. There conclusion that the market for fondaparinux continues to grow,

On recent ASX relaelease on phase III trial. It should not immediately be assumed that the extended time for disease progression overall in the first set of patients is because the patients in the active arm (those taking HA-Irinotecan) are doing better than those in the control arm (HA-Irinotecan). But it is an encouraging sign. (Both groups are also taking the FOLFIRI chemotherapy drug regime).

Also concluded it wouldn't be the interests of shareholders to appoint an internal person into the CEO position